Preclinical data on AbCellera’s PSMA x CD3 T-cell engagers demonstrate potent anti-tumor activity and potential to further enhance function through costimulatory strategies VANCOUVER, BC – AbCellera (Nasdaq: ABCL) announced new… Read More
Company is advancing portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases Lead candidate JADE-001 on track to enter the clinic in… Read More
RESEARCH TRIANGLE PARK, NC – IQVIA™ (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced that Marie… Read More
Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission expected in… Read More
EDMONTON, AB – The Alberta Cancer Foundation and Hoffmann-La Roche Limited (Roche Canada) have announced a new partnership that will see the global life sciences company redirect $1 million of its… Read More
